ECSP15015594A - Piridinonas bicíclicas novedosas - Google Patents

Piridinonas bicíclicas novedosas

Info

Publication number
ECSP15015594A
ECSP15015594A ECIEPI201515594A ECPI201515594A ECSP15015594A EC SP15015594 A ECSP15015594 A EC SP15015594A EC IEPI201515594 A ECIEPI201515594 A EC IEPI201515594A EC PI201515594 A ECPI201515594 A EC PI201515594A EC SP15015594 A ECSP15015594 A EC SP15015594A
Authority
EC
Ecuador
Prior art keywords
relates
neurodegenerative
alzheimer
mammals
disease
Prior art date
Application number
ECIEPI201515594A
Other languages
English (en)
Spanish (es)
Inventor
Tuan Phong Tran
Christopher John O'donnell
Antonia Friederike Stepan
Cory Michael Stiff
Patrick Robert Verhoest
Chakrapani Subramanyam
Martin Youngjin Pettersson
Michael Eric Green
Gregory Wayne Kauffman
Ende Christopher William Am
Nandini Chaturbhai Patel
Douglas Scott Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP15015594A publication Critical patent/ECSP15015594A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
ECIEPI201515594A 2012-09-21 2015-04-20 Piridinonas bicíclicas novedosas ECSP15015594A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261703969P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
ECSP15015594A true ECSP15015594A (es) 2017-08-31

Family

ID=49585452

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201515594A ECSP15015594A (es) 2012-09-21 2015-04-20 Piridinonas bicíclicas novedosas

Country Status (46)

Country Link
US (3) US8916564B2 (index.php)
EP (1) EP2897956B1 (index.php)
JP (1) JP5844018B2 (index.php)
KR (1) KR101725696B1 (index.php)
CN (1) CN104662021B (index.php)
AP (1) AP2015008277A0 (index.php)
AR (1) AR092628A1 (index.php)
AU (1) AU2013319845B2 (index.php)
BR (1) BR112015006436A2 (index.php)
CA (1) CA2882386C (index.php)
CL (1) CL2015000717A1 (index.php)
CR (1) CR20150053A (index.php)
CU (1) CU20150021A7 (index.php)
CY (1) CY1118662T1 (index.php)
DK (1) DK2897956T3 (index.php)
DO (1) DOP2015000069A (index.php)
EA (1) EA026668B1 (index.php)
EC (1) ECSP15015594A (index.php)
ES (1) ES2609987T3 (index.php)
GE (1) GEP201706659B (index.php)
GT (1) GT201500069A (index.php)
HR (1) HRP20161558T1 (index.php)
HU (1) HUE031248T2 (index.php)
IL (1) IL237163A (index.php)
IN (1) IN2015DN01119A (index.php)
LT (1) LT2897956T (index.php)
MA (1) MA37886B1 (index.php)
MD (1) MD4583B1 (index.php)
ME (1) ME02571B (index.php)
MX (1) MX360599B (index.php)
MY (1) MY181891A (index.php)
NI (1) NI201500038A (index.php)
NZ (1) NZ704863A (index.php)
PE (1) PE20150686A1 (index.php)
PH (1) PH12015500376B1 (index.php)
PL (1) PL2897956T3 (index.php)
PT (1) PT2897956T (index.php)
RS (1) RS55426B1 (index.php)
SG (1) SG11201501074WA (index.php)
SI (1) SI2897956T1 (index.php)
TN (1) TN2015000084A1 (index.php)
TW (1) TWI500616B (index.php)
UA (1) UA110688C2 (index.php)
UY (1) UY35039A (index.php)
WO (1) WO2014045156A1 (index.php)
ZA (1) ZA201501195B (index.php)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
HK1212346A1 (en) 2013-01-17 2016-06-10 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
ES2742078T3 (es) * 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
SG11201607465UA (en) * 2014-04-01 2016-10-28 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
BR112017015693A2 (pt) * 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof
JP7018026B2 (ja) 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
CN110337291A (zh) * 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
KR20210084484A (ko) 2018-10-02 2021-07-07 프리퀀시 테라퓨틱스, 인크. 귀 치료제를 포함하는 약제학적 조성물 및 관련 방법
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020210388A1 (en) 2019-04-08 2020-10-15 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN113402490B (zh) * 2021-03-29 2023-01-03 白银京宇新药业有限公司 一种1，2，6，7-四氢-8H-茚并[5，4-b]呋喃-8-酮的制备方法
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
CN114034792B (zh) * 2021-11-09 2024-06-25 山东新华制药股份有限公司 检测氯酮含量的液相色谱分析方法

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419789A (en) 1972-08-02 1975-12-31 Pfizer 2-trifluoromethyl-4-quinolinols
WO1992000075A1 (en) 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
EP0585913B1 (en) 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
ATE242243T1 (de) 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP0994728B1 (en) 1997-04-09 2008-07-30 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE69903715T2 (de) 1998-03-03 2003-08-14 Ppg Industries Ohio, Inc. Imprägnierte glasspinnfäden und diese enthaltende produkte
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
AU1409100A (en) 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002042429A2 (en) 2000-11-03 2002-05-30 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
JP2006506352A (ja) 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物
CA2501945A1 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2003263518A1 (en) 2002-10-09 2004-05-04 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
AU2005208887B2 (en) 2004-01-28 2010-02-25 Merck Sharp & Dohme Corp. Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
JP2007519707A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−３受容体モジュレーター
AU2005227258A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. HIV integrase inhibitors
WO2005092864A1 (en) 2004-03-23 2005-10-06 Pfizer Products Inc. Imidazole compounds for the treatment of neurodegenerative disorders
DK1742642T3 (da) 2004-04-14 2009-02-16 Gilead Sciences Inc Phosphonatanaloge af HIV-integraseinhibitorforbindelser
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7927594B2 (en) 2004-07-30 2011-04-19 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US7741315B2 (en) 2005-05-10 2010-06-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
DK1881985T3 (da) 2005-05-12 2011-02-14 Pfizer Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
US20070060534A1 (en) 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
EP1945639A1 (en) 2005-11-04 2008-07-23 Pfizer Limited Tetrahydronaphthyridine derivative
US20080275251A1 (en) 2005-11-18 2008-11-06 Glaxo Group Limited Novel Intermediates and Their Use
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
NZ568050A (en) 2005-11-24 2010-09-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
EP1976843B1 (en) 2006-01-20 2013-09-04 Merck Sharp & Dohme Corp. Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
MX2008012456A (es) 2006-04-21 2008-10-10 Pfizer Prod Inc Piridin[3,4-b]pirazinonas.
US7442808B2 (en) 2006-05-15 2008-10-28 Merck & Co., Inc. Antidiabetic bicyclic compounds
JP2009537546A (ja) 2006-05-16 2009-10-29 ギリアード サイエンシーズ， インコーポレイテッド インテグラーゼ阻害剤
CN101448793A (zh) 2006-05-19 2009-06-03 卫材R&D管理有限公司 脲型肉桂酰胺衍生物
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2124933B1 (en) 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CA2676920A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
PE20081791A1 (es) 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
US8357682B2 (en) 2007-05-07 2013-01-22 Zhaoning Zhu Gamma secretase modulators
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
AU2008263207B2 (en) 2007-06-01 2013-10-03 Merck Sharp & Dohme Corp. Gamma secretase modulators
BRPI0812491A2 (pt) 2007-06-01 2014-12-02 Schering Corp Moduladores de gama secretase
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
WO2009005729A1 (en) 2007-06-29 2009-01-08 Schering Corporation Gamma secretase modulators
EP2185522A1 (en) 2007-08-06 2010-05-19 Schering Corporation Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
JP5433418B2 (ja) 2007-08-31 2014-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 多環式化合物
CA2698341A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
JP2010540524A (ja) 2007-09-28 2010-12-24 シェーリング コーポレイション ガンマセクレターゼモジュレーター
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
CA2704698A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
CA2707722A1 (en) * 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
CA2708151A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP2231602A1 (en) 2007-12-13 2010-09-29 Amgen, Inc Gamma secretase modulators
RU2010132728A (ru) 2008-01-11 2012-02-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
EP2257541B1 (en) 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
MX2010009454A (es) 2008-02-29 2010-11-25 Schering Corp Moduladores de gamma secretasa para el tratamiento de la enfermedad de alzheimer.
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
CA2722606A1 (en) 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
EP2312946A4 (en) 2008-08-13 2012-10-24 Merck Sharp & Dohme PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
US20110172427A1 (en) 2008-08-27 2011-07-14 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
BRPI0920651A2 (pt) 2008-10-09 2016-01-12 Hoffmann La Roche moduladores para amiloide beta
CA2742602A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
AU2009311756B2 (en) 2008-11-06 2012-05-03 Astrazeneca Ab Modulators of amyloid beta.
US20110263529A1 (en) 2008-11-06 2011-10-27 Ruo Xu Gamma secretase modulators
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
EP2379075A4 (en) 2008-12-16 2012-05-30 Merck Sharp & Dohme TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE
US8575150B2 (en) 2008-12-16 2013-11-05 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of Alzheimer's disease
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
AR074702A1 (es) 2008-12-22 2011-02-02 Schering Corp Moduladores de gamma secretasa y composiciones farmaceuticas que los contienen
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CN102333778B (zh) 2009-02-26 2015-05-13 卫材R&D管理有限公司 四氢三唑并吡啶衍生物的盐及其晶体
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2012121809A (ja) 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
EP2403835A1 (en) 2009-03-03 2012-01-11 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
CN102548411B (zh) 2009-08-07 2014-07-02 陶氏益农公司 杀虫组合物
WO2011048525A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
NZ600954A (en) * 2009-12-22 2013-11-29 Isoindolinone inhibitors of phosphatidylinositol 3-kinase
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
US9181245B2 (en) * 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
HK1212346A1 (en) 2013-01-17 2016-06-10 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
CN106413623B (zh) 2014-03-21 2020-07-03 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
SG11201607465UA (en) 2014-04-01 2016-10-28 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Also Published As

Publication number Publication date
SI2897956T1 (sl) 2017-02-28
EP2897956A1 (en) 2015-07-29
TN2015000084A1 (fr) 2016-06-29
US9193726B2 (en) 2015-11-24
CN104662021A (zh) 2015-05-27
US20160024088A1 (en) 2016-01-28
UA110688C2 (uk) 2016-01-25
MD4583B1 (ro) 2018-07-31
IL237163A (en) 2016-12-29
CA2882386A1 (en) 2014-03-27
KR20150044948A (ko) 2015-04-27
RS55426B1 (sr) 2017-04-28
WO2014045156A1 (en) 2014-03-27
ZA201501195B (en) 2016-01-27
DK2897956T3 (en) 2017-01-16
AP2015008277A0 (en) 2015-02-28
US8916564B2 (en) 2014-12-23
US9751877B2 (en) 2017-09-05
MX2015003637A (es) 2015-06-05
AR092628A1 (es) 2015-04-29
IN2015DN01119A (index.php) 2015-06-26
PH12015500376A1 (en) 2015-04-20
GT201500069A (es) 2016-03-01
CR20150053A (es) 2015-03-25
US20140088111A1 (en) 2014-03-27
PL2897956T3 (pl) 2017-05-31
HUE031248T2 (en) 2017-06-28
TW201425311A (zh) 2014-07-01
ES2609987T3 (es) 2017-04-25
PE20150686A1 (es) 2015-05-23
EP2897956B1 (en) 2016-11-09
HRP20161558T1 (hr) 2016-12-30
AU2013319845B2 (en) 2017-09-14
HK1206013A1 (zh) 2015-12-31
CU20150021A7 (es) 2015-08-27
MX360599B (es) 2018-11-08
MD20150023A2 (ro) 2015-07-31
JP2015529238A (ja) 2015-10-05
EA026668B1 (ru) 2017-05-31
US20150072990A1 (en) 2015-03-12
NZ704863A (en) 2017-03-31
CY1118662T1 (el) 2017-07-12
NI201500038A (es) 2015-06-05
PT2897956T (pt) 2017-01-13
IL237163A0 (en) 2015-04-30
CN104662021B (zh) 2016-08-24
DOP2015000069A (es) 2015-05-15
KR101725696B1 (ko) 2017-04-10
TWI500616B (zh) 2015-09-21
MY181891A (en) 2021-01-12
GEP201706659B (en) 2017-04-25
PH12015500376B1 (en) 2015-04-20
UY35039A (es) 2014-04-30
JP5844018B2 (ja) 2016-01-13
MA37886A1 (fr) 2016-02-29
CL2015000717A1 (es) 2015-06-19
CA2882386C (en) 2017-11-28
AU2013319845A1 (en) 2015-02-26
SG11201501074WA (en) 2015-05-28
MA37886B1 (fr) 2016-09-30
BR112015006436A2 (pt) 2017-07-04
ME02571B (me) 2017-06-20
LT2897956T (lt) 2017-01-10
EA201590319A1 (ru) 2015-09-30

Similar Documents

Publication Publication Date Title
ECSP15015594A (es) Piridinonas bicíclicas novedosas
UY39413A (es) Compuestos inhibidores de metaloenzimas
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
MX2015011434A (es) Partículas inmunomodificadoras para el tratamiento de la inflamación.
MX391536B (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
IN2014DN00286A (index.php)
IN2014MN00093A (index.php)
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
IN2014MN01378A (index.php)
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
IN2014DN06792A (index.php)
CY1117543T1 (el) Αναστολεις βητα-σεκρετασης
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
HK1206612A1 (en) Modified polynucleotides for the production of secreted proteins
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
MX2014011473A (es) Procedimientos y composiciones de tratamiento de enfermedades vasculares arterioscleroticas.
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos